株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Zydus Cadila Healthcare Limited - 製品パイプライン分析

Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224567
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.34円で換算しております。
Back to Top
Zydus Cadila Healthcare Limited - 製品パイプライン分析 Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 84 Pages
概要

Zydus Cadila Healthcare Limited は、医薬品有効成分(API)、製剤、薬用化粧品、動物薬などの製品群で構成する幅広い事業を、開発から販売まで一貫して行っている世界的な製薬会社です。例えば、胃腸、心血管、婦人科系疾患、呼吸器系、疼痛管理、中枢神経系、抗感染症、癌、神経症、皮膚病、腎臓病関連の疾患など様々な治療への応用を対象とした製品を扱っています。

当レポートでは、Zydus Cadila Healthcare Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Zydus Cadila Healthcare Limitedの基本情報

Zydus Cadila Healthcare Limitedの概要

  • 主要情報
  • 企業情報

Zydus Cadila Healthcare Limited:R&Dの概要

  • 主な治療範囲

Zydus Cadila Healthcare Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Zydus Cadila Healthcare Limited:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • IND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Zydus Cadila Healthcare Limited:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

Zydus Cadila Healthcare Limited:薬剤プロファイル

  • interferon beta-1b
  • saroglitazar
  • Vaccine for Live Measles, Mumps and Rubella
  • ZYH-7
  • ZYOG-1
  • PEG-EPO
  • Rabimabs Vaccine
  • Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine
  • Haemophilus Influenzae Type B Conjugated Vaccine
  • Live Attenuated Vaccine for Mumps
  • Live Attenuated Vaccine for Rubella
  • rituximab biosimilar
  • Tetanus Vaccine
  • Toxoid Vaccine for Diptheria and Tetanus
  • Vaccine for Diptheria, Tetanus and Pertussis
  • ZYD-1
  • ZYDPLA-1
  • ZYG-19
  • ZYGK-1
  • ZYPH-0907
  • ZYT-1
  • MAb-3
  • MAb-4
  • Biosimilar 4 for Acute Myocardial Infarction and Infertility
  • Drug for Atherosclerotic Plaque
  • ZYGL-241
  • Biosimilar 1 for Nephrology
  • Biosimilar 2 for Diabetes and Rheumatoid Arthritis
  • Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction
  • Biosimilar 5 for Infertility
  • Biosimilar 6 for Infertility
  • Biosimilar 7 for Infertility and Oncology
  • MAB-6
  • MAb-1
  • MAb-2

Zydus Cadila Healthcare Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Zydus Cadila Healthcare Limited:最近のパイプライン動向

Zydus Cadila Healthcare Limited:休止中のプロジェクト

Zydus Cadila Healthcare Limited:企業発表

Zydus Cadila Healthcare Limited:本社と子会社の所在地

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08182CDB

Summary

Global Markets Direct's, 'Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016', provides an overview of the Zydus Cadila Healthcare Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Zydus Cadila Healthcare Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Zydus Cadila Healthcare Ltd
  • The report provides overview of Zydus Cadila Healthcare Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Zydus Cadila Healthcare Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Zydus Cadila Healthcare Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Zydus Cadila Healthcare Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Zydus Cadila Healthcare Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Zydus Cadila Healthcare Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Zydus Cadila Healthcare Ltd Snapshot
    • Zydus Cadila Healthcare Ltd Overview
    • Key Facts
  • Zydus Cadila Healthcare Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Zydus Cadila Healthcare Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Zydus Cadila Healthcare Ltd - Pipeline Products Glance
    • Zydus Cadila Healthcare Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Ltd - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Zydus Cadila Healthcare Ltd - Drug Profiles
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bevacizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 1 for Nephrology, Acute Myocardial Infarction and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction, Oncology and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 4 for Acute Myocardial Infarction, Infertility, Oncology and Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 5 for Infertility and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 7 for Infertility, Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Crimean-Congo hemorrhagic fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ebola vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Haemophilus influenzae B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis E vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon beta-1b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAb-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAb-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAb-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAb-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • malaria vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEG-EPO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rabimabs - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saroglitazar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • typhoid vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYAN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYDPLA-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYH-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYTP-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Zydus Cadila Healthcare Ltd - Pipeline Analysis
    • Zydus Cadila Healthcare Ltd - Pipeline Products by Target
    • Zydus Cadila Healthcare Ltd - Pipeline Products by Route of Administration
    • Zydus Cadila Healthcare Ltd - Pipeline Products by Molecule Type
    • Zydus Cadila Healthcare Ltd - Pipeline Products by Mechanism of Action
  • Zydus Cadila Healthcare Ltd - Dormant Projects
  • Zydus Cadila Healthcare Ltd - Company Statement
  • Zydus Cadila Healthcare Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zydus Cadila Healthcare Ltd, Key Facts
  • Zydus Cadila Healthcare Ltd - Pipeline by Indication, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Stage of Development, 2016
  • Zydus Cadila Healthcare Ltd - Monotherapy Products in Pipeline, 2016
  • Zydus Cadila Healthcare Ltd - Combination Treatment Modalities in Pipeline, 2016
  • Zydus Cadila Healthcare Ltd - Partnered Products in Pipeline, 2016
  • Zydus Cadila Healthcare Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Zydus Cadila Healthcare Ltd - Pre-Registration, 2016
  • Zydus Cadila Healthcare Ltd - Phase III, 2016
  • Zydus Cadila Healthcare Ltd - Phase II, 2016
  • Zydus Cadila Healthcare Ltd - Phase I, 2016
  • Zydus Cadila Healthcare Ltd - Preclinical, 2016
  • Zydus Cadila Healthcare Ltd - Discovery, 2016
  • Zydus Cadila Healthcare Ltd - Unknown, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Target, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Route of Administration, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Molecule Type, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline Products by Mechanism of Action, 2016
  • Zydus Cadila Healthcare Ltd - Dormant Developmental Projects,2016
  • Zydus Cadila Healthcare Ltd, Other Locations
  • Zydus Cadila Healthcare Ltd, Subsidiaries

List of Figures

  • Zydus Cadila Healthcare Ltd - Pipeline by Top 10 Indication, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Stage of Development, 2016
  • Zydus Cadila Healthcare Ltd - Monotherapy Products in Pipeline, 2016
  • Zydus Cadila Healthcare Ltd - Combination Treatment Modalities in Pipeline, 2016
  • Zydus Cadila Healthcare Ltd - Partnered Products in Pipeline, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Top 10 Target, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Route of Administration, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline by Molecule Type, 2016
  • Zydus Cadila Healthcare Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top